關于保諾-桑迪亞<\/b><\/p> \n
保諾-桑迪亞，安宏資本<\/a>旗下投資企業之一，擁有超過28年的歷史，是一家值得信賴的全球化合同研究、開發和生產公司（CRDMO）。公司總部位于加州爾灣，在中國和美國6個城市設有7個研發生產中心，在全球擁有將近3000名員工。我們為生物技術和制藥企業提供從早期靶點確證到商業化生產的全面整合服務，尤其擅長大小分子發現、開發、放大和生產服務。<\/p> \n 保諾-桑迪亞獨特的技術平臺和整合服務可加速新藥研發進程、降低開發風險，從而創造更高的價值。我們遵循全球高標準的合規和運營準則，科學驅動、以客戶為導向、多元化和以人為本的企業文化。<\/p> \n 保諾-桑迪亞專注于純粹的CRDMO服務，在全球化質量標準體系下運營，提供先進、全面、快速和靈活的定制服務，以滿足生物技術和制藥企業的專屬需求，加快新藥開發進程。如需了解更多信息，請訪問 www.bioduro-sundia.com<\/a>。<\/p> \n 關于DigmBio<\/b><\/p> \n DigmBio, founded in April 2020<\/span>, is a pioneering biotech company headquartered in Korea, dedicated to developing innovative pharmaceuticals targeting critical unmet medical needs. Our management team has decades of collective experience in new drug development and global clinical trials, particularly in small-molecule therapeutics.<\/p> \n DigmBio's primary focus lies in identifying and advancing first-in-class therapeutics with the potential to address unmet medical needs, with a strategic emphasis on leveraging early licensing-out opportunities during the preclinical or phase 1 stages. Their pipeline encompasses therapies for oncology, Alzheimer's disease, and other CNS diseases including Parkinson's disease, along with a KRAS-targeted molecular glue.<\/p>"];
$("#dvExtra").html(content_array[0]);})();